Physician profile
Gilbert Kepecs
NPI 1093710014
$7,889.76
in general payments reported to CMS, 2019-2025
26 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $944 · 2021: $1,003 · 2022: $989 · 2023: $1,330 · 2024: $1,196 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.97 |
| Education | $235.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,891.71 | 2019-2025 | Evenity, Tavneos, Prolia |
| Abbvie INC. | $1,225.06 | 2019-2025 | |
| Janssen Biotech, INC. | $962.74 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $894.37 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $504.90 | 2019-2025 | |
| Pfizer INC. | $401.05 | 2019-2024 | |
| Organon LLC | $280.32 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Lilly USA, LLC | $252.16 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $247.99 | 2019-2024 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $211.13 | 2019-2024 | Orencia |
| Genentech USA, INC. | $210.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $203.45 | 2021-2025 | |
| Genzyme Corporation | $142.11 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2020 | |
| Radius Health, INC. | $83.09 | 2019-2025 | Tymlos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.14 | 2019-2020 | |
| Novo Nordisk INC | $41.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.43 | 2022-2024 | Cyltezo |
| Horizon Therapeutics Plc | $26.90 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $21.66 | 2025 | Lupkynis |
| Ipsen Biopharmaceuticals, INC | $21.54 | 2021 | |
| Invivyd INC | $15.29 | 2025 | Pemgarda |
| Teva Pharmaceuticals USA, INC. | $14.92 | 2022 | |
| Fresenius Kabi USA, LLC | $14.89 | 2024 | Idacio |
| Sandoz INC. | $14.48 | 2024 | Hyrimoz |
| Hikma Pharmaceuticals USA | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Kepecs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.